ISRCTN20367656
Completed
未知
A single centre, placebo controlled trial to investigate the safety and tolerability of bisoprolol in patients with chronic heart failure and chronic obstructive pulmonary disease
Department of Health (UK)0 sites20 target enrollmentSeptember 12, 2003
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Cardiovascular: Heart failure
- Sponsor
- Department of Health (UK)
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Total number of subjects \= 20\.
Exclusion Criteria
- •Does not meet inclusion criteria
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Video image vs virtual reality in theatre to distract children: the VIVID trialChildren undergoing elective or emergency surgeryAnaesthesiology - Other anaesthesiologySurgery - Other surgeryACTRN12622000085774Child & Adolescent Health Service Executive at Perth Children's Hopsital200
Not yet recruiting
Phase 1
A single center, randomized controlled trial on the treatment of elderly patients with acute myeloid leukemia by attack and reinforcement combined with demethylatioITMCTR2000003828Yueyang integrated traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Completed
Not Applicable
Superficial Endometriosis Treatment trialGynaecology - EndometriosisUrological and Genital DiseasesEndometriosisISRCTN37028168Portsmouth Hospitals NHS Trust (UK)32
Completed
Not Applicable
Helping adherence with glaucoma treatment: a randomised trialTopic: Eye, Primary Care Research Network for EnglandSubtopic: Not Assigned, Eye (all Subtopics)Disease: Ophthalmology, All DiseasesEye DiseasesGlaucomaISRCTN89683704orfolk and Norwich University Hospitals NHS Foundation Trust (UK)200
Completed
Not Applicable
A single centre randomised clinical trial to assess the antibody response to a 23-valent pneumococcal polysaccharide vaccine administered to adults aged between 50 - 70 years following a 0, 1 or 2 dose priming immunisation with a 7-valent pneumococcal conjugate vaccineISRCTN78768849niversity of Oxford (UK)348